Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2016 08:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A

SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A,...
March 21, 2016 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)

In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines over Long-Term...
March 03, 2016 08:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Three Upcoming Investor Conferences in March

- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston - Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando ...
March 02, 2016 19:05 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016

80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March...
March 01, 2016 17:42 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A

SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with...
February 29, 2016 08:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients

SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering...
February 29, 2016 08:25 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster

SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the...
February 25, 2016 16:02 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results

- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year - Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line - Full-year 2016 Total...
January 28, 2016 08:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET

SAN RAFAEL, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
January 14, 2016 08:30 ET | Source: BioMarin Pharmaceutical Inc.

FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

SAN RAFAEL, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right